GlassScriptPhysician profile
William Britton Murrill
NPI 1285736173
$4,398.30
in general payments reported to CMS, 2019-2025
30 companies · $305 in 2025
The $305 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $230 · 2021: $721 · 2022: $958 · 2023: $673 · 2024: $929 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,893 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,892.99 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $915.01 | 2019-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $592.20 | 2019-2024 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $393.24 | 2020-2025 | Veltassa, Korsuva |
| Akebia Therapeutics INC | $389.37 | 2019-2024 | Auryxia, Vafseo |
| Amgen INC. | $347.66 | 2019-2024 | Tavneos, Parsabiv, Aranesp |
| Novartis Pharmaceuticals Corporation | $153.61 | 2024-2025 | |
| Medtronic, INC. | $153.59 | 2021 | |
| Bard Peripheral Vascular, INC. | $149.93 | 2019 | |
| Genzyme Corporation | $148.67 | 2019-2025 | |
| Calliditas Therapeutics US INC. | $142.27 | 2022-2023 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $127.84 | 2022-2024 | |
| Baxter Healthcare | $120.22 | 2023 | |
| Mallinckrodt Hospital Products INC. | $97.57 | 2021-2024 | Acthar |
| Otsuka America Pharmaceutical, INC. | $84.08 | 2019-2023 | Jynarque |
| Novo Nordisk INC | $71.35 | 2024-2025 | Ozempic, Rybelsus |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $70.08 | 2019-2022 | |
| Horizon Therapeutics Plc | $66.72 | 2019-2023 | Krystexxa |
| Abiomed | $60.22 | 2020 | |
| Alexion Pharmaceuticals, INC. | $55.60 | 2021-2023 | Ultomiris |
| Daiichi Sankyo INC. | $49.73 | 2020-2022 | |
| Aurinia Pharma U.S., INC. | $43.28 | 2022-2024 | Lupkynis |
| Glaxosmithkline, LLC. | $30.50 | 2023-2024 | Jesduvroq, Benlysta |
| Veloxis Pharmaceuticals, INC. | $21.90 | 2020 | |
| Pharmacosmos Therapeutics INC. | $20.90 | 2021 | |
| Ardelyx, INC. | $18.59 | 2024 | Ibsrela |
| Lilly USA, LLC | $17.85 | 2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $16.91 | 2024 | Keveyis |
| Strongbridge US INC. | $14.49 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.13 | 2024 | Jardiance |
| La Jolla Pharmaceutical Company | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Murrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.